Indication

BENLYSTA® is indicated to treat:

  • System Lupus Erythmatosus

Drug Summary

BENLYSTA, Belimumab, is an immunosuppressive drug used to treat active Systemic Lupus Erythematosus. Administration of BENLYSTA follows an induction regimen of 3 intravenous infusions at 2-week intervals followed by a maintenance infusion, once every 4 weeks.

 

More Information

For more information, click here to visit the manufacturer’s website: https://www.benlysta.com/

Ready to Start with Specialty Infusion?

It’s easy to transition your treatment to Specialty Infusion. Here’s how it works:

Ask your doctor to send a prescription, clinical notes, demographics and your insurance card.

One of our Care Coordinators will contact you to confirm receipt of your referral and provide guidance on the next steps.

Your Care Coordinator will contact your insurance company to conduct an investigation of benefits and initiate authorization to ensure coverage of your treatment.

Our team works diligently to expedite the authorization process. Once approval is obtained, your Care Coordinator will contact you to schedule an appointment.